Autolus Pioneers CAR-T Cell MS Treatment
- brucelynn
- Mar 5
- 1 min read
QSA congratulates Autolus for achieving its historic milestone dosing the first patient with its pioneering BOBCAT trial of obecabtagene autoleucel (obe-cel), a ‘one-time’ immunotherapy treatment for progressive multiple sclerosis (PMS). QSA is providing advanced imaging analytics in support of this groundbreakig work.
Comments